IBA - Taking a new step in the Actinium journey
IBA announced that PanTera has signed a strategic partnership with TerraPower to increase the availability of actinium-225. In the short-term, PanTera will use TerraPower's technology to produce actinium-225. We believe it will allow them to start building a relationship with drug developers, making a first step towards securing potential future supply agreements. Both companies will switch to PanTera's technology, once this is fully up and running, which is expected by 2027. No impact on valuation for now. IBA indicates that although the collaboration will not have immediate financial impact, it has the potential to bring substantial revenues in the futureIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.